N-Methyl-D-aspartic acid

Relmada Therapeutics to Report Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 10, 2021

Retrieved on: 
Thursday, August 5, 2021
Company, Nature, NCE, Phrase, Private Securities Litigation Reform Act, Risk, MDD, Securities Act of 1933, Patient, Securities Exchange Act of 1934, CNS, N-Methyl-D-aspartic acid, SEC, Central nervous system, Lists of diseases, Therapy, NMDA receptor, Pharmaceutical industry, Audit, Risk management

Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD).

Key Points: 
  • Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD).
  • Our experienced and dedicated team is committed to making a difference in the lives of patients and their families.
  • Relmada' s lead program, REL-1017, is a new chemical entity (NCE) and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission.
  • Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Schizophrenia Drug Pipeline Market Research Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Thursday, August 5, 2021
Pharmaceutical, Health, Mental Health, TAAR1, M1, Teva Pharmaceuticals, CYP2D6, United States, Brain, Dnata Singapore, Route, Boehringer Ingelheim, Administration, Therapy, Route of administration, Patient, US Foods, Merck Sharp & Dohme Federal Credit Union, Agonist, Government budget balance, Biotinidase, M4, N-Methyl-D-aspartic acid, Hallucination, Intention, Cognition, Food and Drug Administration, Alzheimer's disease, 5-HT2A receptor, Deuterium, Agitation, Delusion, PDE10A, NDA, Breakthrough therapy, Psychosis, Food, Movement disorders, Risperidone, Pharmaceutical industry, Medical device

The "Schizophrenia - Pipeline Insight, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Schizophrenia - Pipeline Insight, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.
  • This Schizophrenia - Pipeline Insight, 2021 provides comprehensive insights about 70+ companies and 70+ pipeline drugs in Schizophrenia pipeline landscape.
  • The companies which have their Schizophrenia drug candidates in the most advanced stage, i.e.
  • Schizophrenia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

PharmaTher Granted FDA Orphan Drug Designation For Ketamine To Treat Amyotrophic Lateral Sclerosis

Retrieved on: 
Wednesday, August 4, 2021
Health sciences, Health, Food and Drug Administration, Life sciences, Pharmaceuticals policy, Drug discovery, Biotechnology law, Orphan drug, Orphan Drug Act, Clinical trial, Food and Drug Administration Safety and Innovation Act, Breakthrough therapy

The FDA evaluated the research data licensed from KU in the ODD application that ultimately served as the foundation to allow the FDA to grant the designation.

Key Points: 
  • The FDA evaluated the research data licensed from KU in the ODD application that ultimately served as the foundation to allow the FDA to grant the designation.
  • The Orphan Drug Act grants special status to a drug or biological product to treat a rare disease or condition upon request of a sponsor.
  • The FDA grants orphan status to products that treat rare diseases, providing incentives to sponsors developing drugs or biologics.
  • PharmaTher is currently initiating an FDA approved phase 2 clinical study with ketamine to treat Parkinsons disease and is developing a novel microneedle patch for the intradermal delivery of psychedelics.

Relmada Therapeutics Announces the Acquisition of Development and Commercial Rights to Novel Psilocybin and Derivates Program from Arbormentis LLC

Retrieved on: 
Tuesday, July 20, 2021
Branches of biology, Psychoactive drugs, Neurochemistry, NMDA receptor antagonists, Glutamate, Ionotropic glutamate receptors, Neurotransmitters, NMDA receptor, N-Methyl-D-aspartic acid, Ketamine

Arbormentis LLC is also eligible to receive a low single digit royalty on any commercialized therapy resulting from this agreement.

Key Points: 
  • Arbormentis LLC is also eligible to receive a low single digit royalty on any commercialized therapy resulting from this agreement.
  • Arbormentis LLC is a privately-held drug discovery company engaged in potentially transformative innovations for CNS diseases.
  • Relmada' s lead program, REL-1017, is a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission.
  • Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Relmada Therapeutics Announces Participation in Goldman Sachs 42nd Annual Global Healthcare Conference

Retrieved on: 
Monday, June 7, 2021
Branches of biology, Glutamate, Biology, NMDA receptor antagonists, Molecular neuroscience, Ionotropic glutamate receptors, NMDA receptor, N-Methyl-D-aspartic acid

An archived replay of the event will be available for one year after the conclusion of the presentation.

Key Points: 
  • An archived replay of the event will be available for one year after the conclusion of the presentation.
  • Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD).
  • Relmada' s lead program, REL-1017, is a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission.
  • Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Relmada Therapeutics to Report First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 12, 2021

Retrieved on: 
Thursday, May 6, 2021
Branches of biology, Drugs, NMDA receptor antagonists, Psychoactive drugs, Glutamate, Ionotropic glutamate receptors, Cell signaling, NMDA receptor, N-Methyl-D-aspartic acid, Forward-looking statement, Ketamine, Channel blocker

Our experienced and dedicated team is committed to making a difference in the lives of patients and their families.

Key Points: 
  • Our experienced and dedicated team is committed to making a difference in the lives of patients and their families.
  • Relmada\' s lead program, REL-1017, is a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission.
  • No forward-looking statement can be guaranteed, and actual results may differ materially from those projected.
  • Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Relmada Therapeutics Announces Poster Presentations at the American Psychiatric Association Annual Meeting 2021

Retrieved on: 
Saturday, May 1, 2021
Branches of biology, Drugs, Psychoactive drugs, NMDA receptor antagonists, Glutamate, Ionotropic glutamate receptors, General anesthetics, Nicotinic antagonists, NMDA receptor, Ketamine, N-Methyl-D-aspartic acid, Antidepressant

In a Phase 2 trial, REL-1017 demonstrated rapid onset and sustained antidepressant effects with statistically significant improvements as compared to placebo.

Key Points: 
  • In a Phase 2 trial, REL-1017 demonstrated rapid onset and sustained antidepressant effects with statistically significant improvements as compared to placebo.
  • The Phase 2 study also confirmed the favorable safety and tolerability profile of REL-1017 observed in previously completed Phase 1 studies.
  • Relmada\' s lead program, REL-1017, is a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission.
  • Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Relmada Therapeutics Announces Poster Presentations at the 2021 Society of Biological Psychiatry Annual Meeting

Retrieved on: 
Thursday, April 29, 2021
Branches of biology, Drugs, Psychoactive drugs, NMDA receptor antagonists, Glutamate, Ionotropic glutamate receptors, General anesthetics, Nicotinic antagonists, NMDA receptor, Ketamine, N-Methyl-D-aspartic acid, Antidepressant

In a Phase 2 trial, REL-1017 demonstrated rapid onset and sustained antidepressant effects with statistically significant improvements as compared to placebo.

Key Points: 
  • In a Phase 2 trial, REL-1017 demonstrated rapid onset and sustained antidepressant effects with statistically significant improvements as compared to placebo.
  • The Phase 2 study also confirmed the favorable safety and tolerability profile of REL-1017 observed in previously completed Phase 1 studies.
  • Relmada\' s lead program, REL-1017, is a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission.
  • Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Relmada Therapeutics Announces Participation in the 7th Annual Truist Securities Life Sciences Summit

Retrieved on: 
Wednesday, April 28, 2021
Branches of biology, Psychoactive drugs, Drugs, NMDA receptor antagonists, Glutamate, Molecular neuroscience, Antidepressants, Ionotropic glutamate receptors, NMDA receptor, N-Methyl-D-aspartic acid, Ketamine

The webcast will be available for 90 days after the presentation.\nRelmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD).

Key Points: 
  • The webcast will be available for 90 days after the presentation.\nRelmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD).
  • Our experienced and dedicated team is committed to making a difference in the lives of patients and their families.
  • Relmada\' s lead program, REL-1017, is a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission.
  • Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Relmada Therapeutics to Report Fourth Quarter and Full-Year 2020 Financial Results and Host Conference Call and Webcast on March 23, 2021

Retrieved on: 
Thursday, March 18, 2021
Branches of biology, Drugs, Neurochemistry, NMDA receptor antagonists, Glutamate, Ionotropic glutamate receptors, Molecular neuroscience, NMDA receptor, Ketamine, N-Methyl-D-aspartic acid

Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD).

Key Points: 
  • Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD).
  • Our experienced and dedicated team is committed to making a difference in the lives of patients and their families.
  • Relmada' s lead program, REL-1017, is a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission.
  • Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.